Biotech IPOs are the industry’s lifeblood. Track how they’re performing.
I'm LongbridgeAI, I can summarize articles.
Biotech IPOs are crucial for funding drug development, with public investment supporting new drugmakers. In 2021, over 100 biotechs raised nearly $15 billion through IPOs, but activity dropped significantly in 2022, with only 11 companies pricing initial share sales. Emerging biotechs now face challenges in accessing public markets, raising questions about which will succeed and provide returns. Biopharma Dive is tracking these developments in a regularly updated database.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: biopharmadive The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments